5E729BD1-654D-4334-A80F-3EDD472551B4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.164257555847569
- age_years
- 51
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.717
- G2M_CHECKPOINT+0.623
- MYC_TARGETS_V1+0.567
- MYC_TARGETS_V2+0.532
- DNA_REPAIR+0.523
- MTORC1_SIGNALING+0.425
- ANGIOGENESIS+0.423
- UNFOLDED_PROTEIN_RESPONSE+0.363
- MITOTIC_SPINDLE+0.329
- CHOLESTEROL_HOMEOSTASIS+0.319
Top 10 suppressed
- KRAS_SIGNALING_DN-0.317
- BILE_ACID_METABOLISM-0.282
- MYOGENESIS-0.247
- APICAL_SURFACE-0.245
- INFLAMMATORY_RESPONSE-0.216
- HEME_METABOLISM-0.202
- ESTROGEN_RESPONSE_EARLY-0.190
- UV_RESPONSE_DN-0.144
- ALLOGRAFT_REJECTION-0.125
- COAGULATION-0.115
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.918 |
| 2 | 109ABE6B-033D-47E8-A03A-D285BE82C17B | — | — | 0.905 |
| 3 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.892 |
| 4 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.891 |
| 5 | 113340B4-B092-4B8C-8A13-5932525B0C33 | — | — | 0.887 |
| 6 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.881 |
| 7 | C8E7072F-6FBB-4BF8-8917-0C0CBDAF7605 | — | — | 0.872 |
| 8 | 5B4B7A3B-FD69-43EA-9C9C-FBE2845046CB | — | — | 0.867 |
| 9 | 8F828A42-3E60-40C1-9E7D-428ABEA6C72F | — | — | 0.863 |
| 10 | SRR934893 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.717 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.623 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.567 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.532 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.523 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.425 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.423 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.363 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.329 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.319 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.315 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.279 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.266 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.257 | Idelalisib | — uncovered |
| HYPOXIA | 0.246 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.235 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.231 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.192 | Inavolisib | — uncovered |
| APOPTOSIS | 0.183 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.145 | Idelalisib | — uncovered |